^
    Back
    Association details:
    Biomarker:GPNMB expression
    Cancer:Uveal Melanoma
    Drug:glembatumumab vedotin (CDX-011) (Microtubule inhibitor, GPNMB-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

    Excerpt:
    ...The Number of Participants With Change in Glycoprotein NMB Expression on Tumor Tissue Via Immunohistochemistry`Progression-free Survival`Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0`Overall Survival...
    Trial ID:
    NCT02363283
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

    Excerpt:
    This phase II study evaluated the overall response rate and safety of GV, glycoprotein NMB (GPNMB) expression, and survival in patients with metastatic uveal melanoma….Out of 35 patients who received treatment, two patients had confirmed partial responses (PRs; 6%), and 18 patients had a stable disease (SD; 51%) as the best objective response. 38% of the patients had stable disease >100 days....GV is well-tolerated in metastatic uveal melanoma. The disease control rate was 57% despite a low objective response rate.
    DOI:
    https://doi.org/10.3390/cancers12082270